UBS (Lux) Equity SICAV - European Opportunity Unconstrained (EUR) P-accRegister to Unlock Ratings |
Performance History | 31/03/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 15.2 | 16.9 | -12.9 | 2.8 | 7.0 | |
+/-Cat | 10.9 | 1.6 | -4.6 | -8.7 | 1.3 | |
+/-B’mrk | 12.6 | -0.8 | -8.3 | -10.4 | 0.7 | |
Category: Europe Large-Cap Blend Equity | ||||||
Category Benchmark: Morningstar DM Eur TME NR EUR |
Key Stats | ||
NAV 22/04/2024 | EUR 282.34 | |
Day Change | 1.62% | |
Morningstar Category™ | Europe Large-Cap Blend Equity | |
ISIN | LU0723564463 | |
Fund Size (Mil) 22/04/2024 | EUR 551.16 | |
Share Class Size (Mil) 22/04/2024 | EUR 184.65 | |
Max Initial Charge | 5.00% | |
Ongoing Charge 27/03/2024 | 2.00% |
Investment Objective: UBS (Lux) Equity SICAV - European Opportunity Unconstrained (EUR) P-acc |
This actively managed sub-fund predominantly invests in equities, equity rights or other equity interests in companies domiciled or chiefly active in Europe. The UBS ESG consensus score is used to identify issuers/companies for the investment universe with strong environmental and social performance characteristics, or a strong sustainability profile. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Maximilian Anderl 23/07/2012 | ||
Jeremy Leung 01/04/2011 | ||
Inception Date 14/06/2012 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
MSCI Europe NR EUR | Morningstar DM Eur TME NR EUR |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for UBS (Lux) Equity SICAV - European Opportunity Unconstrained (EUR) P-acc | 31/03/2024 |
|
|
Top 5 Holdings | Sector | % |
Novo Nordisk A/S Class B | Healthcare | 5.05 |
UBS (Irl) Inv Sel Eq Opp L/S € U-B | 4.08 | |
Lvmh Moet Hennessy Louis Vuitton SE | Consumer Cyclical | 3.71 |
ASML Holding NV | Technology | 3.48 |
Tryg A/S | Financial Services | 2.98 |
Increase Decrease New since last portfolio | ||
UBS (Lux) Equity SICAV - European Opportunity Unconstrained (EUR) P-acc |